Conference call to provide an EDIT-301 clinical update on December 6 at 8 am. Webcast Link
Published first on TheFly
See the top stocks recommended by analysts >>
Read More on EDIT:
- Editas Medicine’s EDIT-301 shows safety and efficacy in sickle cell disease
- Editas Medicine Announces Positive Safety and Efficacy Data from the First Two Patients Treated in the RUBY Trial of EDIT-301 for the Treatment of Severe Sickle Cell Disease
- Editas Medicine to host conference call
- Editas Medicine assumed with a Neutral at Credit Suisse
- Editas Medicine to Host Virtual Event to Highlight Initial Clinical Data from the RUBY Trial of EDIT-301 for Severe Sickle Cell Disease
Questions or Comments about the article? Write to editor@tipranks.com